Clinical Trials Browser

Interventional × Neoplasms × LMB-100 × Clear all

NCT02810418 2022-03-15

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Phase 1/2 Completed

40 enrolled 37 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT02317419 2016-07-26

A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

Phase 1 Terminated

Neoplasms